TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
TNF Pharmaceuticals, formerly MyMD Pharmaceuticals, has begun trading under its new Nasdaq stock symbol TNFA as of July 24, 2024. This change reflects the company's focus on inhibiting TNF-alpha to regulate the immuno-metabolic system. The company's lead clinical candidate, MYMD-1, blocks excess TNF-α activity, potentially restoring immune system control and regulation.
Dr. Mitchell Glass, President and Chief Medical Officer, emphasized that this rebranding aligns with their core science and highlights MYMD-1's potential as the first TNF-α inhibitor in its indication. The company's CUSIP remains unchanged, and current stockholders need not take any action regarding the symbol change.
TNF Pharmaceuticals, precedentemente MyMD Pharmaceuticals, ha iniziato a essere quotata con il suo nuovo simbolo di borsa Nasdaq TNFA a partire dal 24 luglio 2024. Questo cambiamento riflette il focus dell'azienda nell'inibire il TNF-alfa per regolare il sistema immuno-metabolico. Il candidato clinico principale dell'azienda, MYMD-1, blocca l'attività eccessiva del TNF-α, potenzialmente ripristinando il controllo e la regolazione del sistema immunitario.
Il Dr. Mitchell Glass, Presidente e Direttore Medico, ha sottolineato che questo rebranding è in linea con la loro scienza fondamentale e mette in evidenza il potenziale di MYMD-1 come il primo inibitore del TNF-α nella sua indicazione. Il CUSIP dell'azienda rimane invariato e gli attuali azionisti non devono intraprendere alcuna azione riguardo il cambiamento di simbolo.
TNF Pharmaceuticals, anteriormente MyMD Pharmaceuticals, ha comenzado a cotizar bajo su nuevo símbolo bursátil en Nasdaq TNFA a partir del 24 de julio de 2024. Este cambio refleja el enfoque de la compañía en inhibir el TNF-alfa para regular el sistema inmuno-metabólico. El principal candidato clínico de la compañía, MYMD-1, bloquea la actividad excesiva de TNF-α, potencialmente restaurando el control y la regulación del sistema inmunológico.
El Dr. Mitchell Glass, Presidente y Director Médico, enfatizó que esta nueva marca está alineada con su ciencia fundamental y resalta el potencial de MYMD-1 como el primer inhibidor de TNF-α en su indicación. El CUSIP de la compañía permanece sin cambios, y los accionistas actuales no necesitan tomar ninguna acción respecto al cambio de símbolo.
TNF 제약, 이전의 MyMD 제약,은 2024년 7월 24일부터 새로운 나스닥 주식 기호 TNFA로 거래를 시작했습니다. 이 변화는 면역 대사 시스템을 조절하기 위해 TNF-alpha를 억제하는 데 회사의 초점을 반영합니다. 회사의 주요 임상 후보 물질인 MYMD-1은 TNF-α의 과도한 활동을 차단하여 면역 체계의 조절과 제어를 복원할 수 있습니다.
Mitchell Glass 박사, 사장 겸 최고 의료 책임자는 이번 리브랜딩이 그들의 핵심 과학과 일치하며 MYMD-1이 해당 적응증에서 첫 번째 TNF-α 억제제로서의 잠재력을 강조한다고 강조했습니다. 회사의 CUSIP는 변경되지 않으며 현재 주주들은 기호 변경에 대해 아무런 조치를 취할 필요가 없습니다.
TNF Pharmaceuticals, anciennement MyMD Pharmaceuticals, a commencé à négocier sous son nouveau symbole boursier Nasdaq TNFA à partir du 24 juillet 2024. Ce changement reflète l’accent mis par l’entreprise sur l’inhibition du TNF-alpha pour réguler le système immuno-métabolique. Le principal candidat clinique de l’entreprise, MYMD-1, bloque l'activité excessive du TNF-α, permettant potentiellement de restaurer le contrôle et la régulation du système immunitaire.
Dr. Mitchell Glass, Président et Directeur Médical, a souligné que ce rebranding est en accord avec leur science fondamentale et met en avant le potentiel de MYMD-1 en tant que premier inhibiteur de TNF-α dans son indication. Le CUSIP de l'entreprise reste inchangé et les actionnaires actuels n'ont besoin d'aucune action concernant le changement de symbole.
TNF Pharmaceuticals, ehemals MyMD Pharmaceuticals, hat am 24. Juli 2024 mit dem Handel unter ihrem neuen Nasdaq-Aktienkürzel TNFA begonnen. Diese Änderung spiegelt den Fokus des Unternehmens wider, TNF-alpha zu hemmen, um das immuno-metabolische System zu regulieren. Der Hauptkandidat des Unternehmens, MYMD-1, blockiert die übermäßige TNF-α-Aktivität und kann potenziell die Kontrolle und Regulation des Immunsystems wiederherstellen.
Dr. Mitchell Glass, Präsident und Chief Medical Officer, betonte, dass dieses Rebranding mit ihrer Kernwissenschaft übereinstimmt und das Potenzial von MYMD-1 als den ersten TNF-α-Hemmer in seiner Indikation hervorhebt. Die CUSIP-Nummer des Unternehmens bleibt unverändert, und die aktuellen Aktionäre müssen hinsichtlich des Symbolwechsels keine Maßnahmen ergreifen.
- Rebranding aligns with the company's scientific focus on TNF-alpha inhibition
- Lead candidate MYMD-1 shows potential as first TNF-α inhibitor in its indication
- No action required from current stockholders regarding symbol change
- None.
As a financial analyst, I find this news to be of immediate impact on TNF Pharmaceuticals' financial performance. The change in ticker symbol and company name is primarily a branding exercise, aligning the company's identity with its scientific focus on TNF-alpha inhibition.
However, this rebranding could have some indirect benefits:
- Improved investor recognition: The new name and ticker symbol may attract investors specifically interested in TNF-alpha targeted therapies, potentially increasing visibility in the biotech investment community.
- Clearer market positioning: By emphasizing their focus on TNF-alpha, the company may differentiate itself more effectively from competitors, which could influence investor perception and valuation multiples.
- Alignment with clinical progress: The timing of this change suggests confidence in the ongoing development of MYMD-1, their lead candidate. This could be a positive signal for investors tracking the company's clinical pipeline.
It's important to note that while rebranding can influence market perception, the true value drivers for TNF Pharmaceuticals will continue to be its clinical trial results, regulatory approvals and eventual commercialization success. Investors should focus on these fundamental factors rather than being swayed by the name change alone.
In terms of financial impact, there may be some short-term costs associated with the rebranding effort, but these are likely to be minimal in the context of the company's overall R&D expenses. The long-term financial implications will depend on how effectively the company leverages this new identity to support its business objectives and attract investment.
From a medical research perspective, TNF Pharmaceuticals' rebranding underscores the growing importance of TNF-alpha as a therapeutic target in age-related diseases and autoimmune conditions. This focus is scientifically sound, given the well-established role of TNF-alpha in inflammation and autoimmunity.
The company's lead candidate, MYMD-1, is particularly interesting as it aims to block excess TNF-alpha activity. This approach differs from existing TNF-alpha inhibitors in several ways:
- Selectivity: MYMD-1 may offer more targeted inhibition of TNF-alpha, potentially reducing side effects associated with broader immunosuppression.
- Novel indications: The company's focus on age-related diseases suggests they're exploring new therapeutic applications for TNF-alpha inhibition beyond traditional autoimmune conditions.
- Oral administration: If successful, an orally administered TNF-alpha inhibitor could offer significant advantages over injectable biologics in terms of patient convenience and compliance.
However, it's important to note that the success of MYMD-1 will ultimately depend on robust clinical data demonstrating safety and efficacy. The rebranding doesn't provide new information about the drug's performance or potential.
Investors should closely monitor upcoming clinical trial results, particularly any data on MYMD-1's ability to modulate the immuno-metabolic system effectively. The company's success will hinge on demonstrating clear therapeutic benefits and a favorable safety profile compared to existing treatments.
While the rebranding aligns the company more closely with its scientific focus, it doesn't change the fundamental challenges and opportunities in developing novel TNF-alpha inhibitors. The path to regulatory approval and market success remains long and uncertain, as is typical in biopharmaceutical development.
New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
The new trading symbol “TNFA” replaces the Company’s previous trading symbol “MYMD” and coincides with the Company’s previously announced corporate name change to TNF Pharmaceuticals, Inc. The new corporate identity more accurately aligns with the Company’s scientific focus on TNF-alpha (TNF-alpha tumor necrosis factor-alpha, or TNF-α), a protein in the body that plays a key role in inflammation and autoimmunity. The Company’s lead clinical candidate, MYMD-1®, blocks the activity of excess TNF-α, which supports restoration of control and regulation of the immune system.
“Our Company’s new name and stock identity comes at an important time in our clinical development of MYMD-1, illuminating both our core science and our clinical candidate’s strong potential to be the first TNF-α inhibitor in this indication,” said the Company’s President, Chief Medical Officer and Director, Mitchell Glass, M.D.
Effective today, all stock trading, Securities and Exchange Commission filings and market-related information will be reported under the new trading symbol “TNFA.” The CUSIP for the Company's common stock is unchanged. There is no action required by the Company’s current stockholders with respect to the trading symbol change.
About TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), formerly known as MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.tnfpharma.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724213342/en/
Robert Schatz
(646) 421-9523
rschatz@tnfpharma.com
www.tnfpharma.com
Source: TNF Pharmaceuticals, Inc.
FAQ
When did TNF Pharmaceuticals (TNFA) start trading under its new Nasdaq symbol?
What was TNF Pharmaceuticals' previous stock symbol before changing to TNFA?
What is the main focus of TNF Pharmaceuticals (TNFA)?
What is the lead clinical candidate of TNF Pharmaceuticals (TNFA)?
